Evoke Pharma, Inc. (EVOK)
| Previous close | 1.0900 |
| Open | 1.0600 |
| Bid | 1.0000 x 1000 |
| Ask | 1.1500 x 1100 |
| Day's range | 1.0100 - 1.1100 |
| 52-week range | 0.9190 - 5.9600 |
| Volume | |
| Avg. volume | 12,643 |
| Market cap | 3.377M |
| Beta (5Y monthly) | 0.36 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.3100 |
| Earnings date | 07 Nov 2023 - 13 Nov 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 7.00 |
GlobeNewswireEvoke Pharma Receives Notice of Allowance from USPTO for GIMOTI®
SOLANA BEACH, Calif., Sept. 14, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, announced that it has been granted a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for patent application No. 17/366,829 pertaining to GIMOTI, the first and only FDA-approved nasal formulation of metoclopramide commercially
- GlobeNewswire
Evoke Pharma Reports Second Quarter 2023 Financial Results
40% revenue growth compared to Q1 2023 34% increase in prescription fills compared to Q1 2023 Presented industry-leading real-world healthcare utilization data supporting the benefits of GIMOTI compared to oral metoclopramide at DDW 2023; additional abstracts accepted at future medical conferences SOLANA BEACH, Calif., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an
- GlobeNewswire
Evoke Pharma and EVERSANA Announce Abstract Acceptance at 2023 American Neurogastroenterology and Motility Society (ANMS) Meeting
Real-world study that explored the healthcare utilization resource utilization among patients receiving GIMOTI with and without prior treatment with oral metoclopramide Both organizations recognize and support Gastroparesis Awareness Month through continued support of the International Foundation for Gastrointestinal Disorders (IFFGD) SOLANA BEACH, Calif. and CHICAGO, Aug. 07, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on trea
